SAB Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary

SAB Biotherapeutics

21/08/2023 14:32

* SAB Biotherapeutics Inc  SABS.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 14 cents per share.
    * Revenue fell 98.7% to $85.52 thousand from a year ago;
analysts
expected $406.67 thousand. 
    * SAB Biotherapeutics Inc's reported EPS for the quarter was
a
loss of 14 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * SAB Biotherapeutics Inc shares had fallen by 8.3% this
quarter and gained 29.0% so far this year.
    * The company reported a quarterly loss of $6.88 million.
    * Wall Street's median 12-month price target for SAB
Biotherapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 21 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.14          -0.14          Met
 Mar. 31 2023      -0.08          -0.15          Missed
 Dec. 31 2022      -0.03                         
 Sep. 30 2022      -0.16          -0.16          Met